GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hypera SA (BSP:HYPE3) » Definitions » YoY EBITDA Growth

Hypera (BSP:HYPE3) YoY EBITDA Growth : -115.21% (As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Hypera YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Hypera's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -115.21%.

Hypera's EBITDA per Share for the three months ended in Mar. 2025 was R$-0.17.

Hypera YoY EBITDA Growth Historical Data

The historical data trend for Hypera's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypera YoY EBITDA Growth Chart

Hypera Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.23 39.98 28.09 4.23 -22.46

Hypera Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.26 -4.00 -26.67 -77.09 -115.21

Hypera YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Hypera's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(3.498-4.511)/ | 4.511 |
=-22.46 %

Hypera's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (Q: Mar. 2025 )
=(EBITDA per Share (Q: Mar. 2025 )-EBITDA per Share (Q: Mar. 2024 )) / | EBITDA per Share (Q: Mar. 2024 )) |
=(-0.167-1.098)/ | 1.098 |
=-115.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hypera YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Hypera's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Hypera Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hypera SA (BSP:HYPE3) » Definitions » YoY EBITDA Growth
Comparable Companies
BSP:BLAU3 BSP:OFSA3 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124
Traded in Other Exchanges
HYPMY:USA HM6A:Germany
Address
Avenida Magalhaes de Castro, 4800, 240 Floor Continental Tower Building, Bairro Cidade Jardim, Sao Paulo, SP, BRA, CEP 05676-120
Website
https://www.hypermarcas.com.br
Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and the Non-Retail Market.

Hypera Headlines

No Headlines